NRDC

Nardilysin · O43847 · NRDC on Sugi Atlas →

0 patent compounds predicted against NRDC, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NRDC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) PHASE4NOT_YET_RECRUITING
Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure PHASE3COMPLETED
Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia PHASE3COMPLETED
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI PHASE3COMPLETED
Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT PHASE2/PHASE3UNKNOWN
Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke PHASE3COMPLETED
Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure PHASE3COMPLETED
Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. PHASE3UNKNOWN
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients. PHASE3COMPLETED
Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration PHASE2COMPLETED
the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome PHASE2COMPLETED
FITMI - First In Treating Male Infertility PHASE2ACTIVE_NOT_RECRUITING
Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study PHASE1/PHASE2UNKNOWN
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) PHASE2COMPLETED
CD-NP in Subjects With Stable Chronic Heart Failure PHASE1COMPLETED
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing PHASE1COMPLETED
Cerebrolysin and Neurodevelopment in Preterm Infants PHASE1COMPLETED
Effects of Different Forms of a Natural Heart Hormone on Blood Pressure and Fluid Balance in Healthy Volunteers EARLY_PHASE1COMPLETED
Neuregulin-1 in Patient With Different Forms of Cardiovascular Diseases: a Pilot Study nanCOMPLETED
Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus nanCOMPLETED
Ankle Brachial Index Versus Conventional Cardiac Risk Indices nanUNKNOWN
Presepsin:Gelsolin Ratio in Sepsis-related Organ Dysfunction nanCOMPLETED
Effects of Nesiritide in Pediatric Patients With Heart Failure nanWITHDRAWN
Pharmacodynamics of CNP During Growth Hormone Treatment nanCOMPLETED
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia nanRECRUITING
Efficacy of a Rinse Containing Sea Salt and Lysozyme on Biofilm and Gingival Health nanCOMPLETED
Cardiotoxicity of Cancer Therapy (CCT) nanENROLLING_BY_INVITATION
Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension nanWITHDRAWN
A Cut-off Value Study of N-terminal Brain Natriuretic Peptide (Chemiluminescence Method) nanCOMPLETED
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NRDC binder may also engage these)

ProteinNameSimilarity
Q5R4H6 1.000 Q5R4H6 →
Q8BHG1 0.996 Q8BHG1 →
P47245 0.992 P47245 →
P20069 0.936 P20069 →
Q9DC61 0.924 Q9DC61 →
Q91YD4 0.924 Q91YD4 →
Q10713 0.921 Q10713 →
Q5R513 0.921 Q5R513 →
Q4R766 0.920 Q4R766 →
Q6AYT7 0.920 Q6AYT7 →
Q7SXS7 0.919 Q7SXS7 →
Q99LR1 0.918 Q99LR1 →
B0VX69 0.918 B0VX69 →
Q5U4X8 0.918 Q5U4X8 →
E9PTA2 0.918 E9PTA2 →
Q9H3R1 0.918 Q9H3R1 →
Q0P5M8 0.918 Q0P5M8 →
B7ZUF3 0.917 B7ZUF3 →
G3V6U9 0.917 G3V6U9 →
TRPC3 Short transient receptor potential channel 3 0.917 landscape →
Q9QZC1 0.916 Q9QZC1 →
Q923S8 0.916 Q923S8 →
TRPM2 Transient receptor potential cation channel subfamily M member 2 0.916 landscape →
Q4R4U1 0.916 Q4R4U1 →
Q5R5F8 0.915 Q5R5F8 →
B5FW36 0.915 B5FW36 →
Q9NVE7 0.915 Q9NVE7 →
Q9EQW8 0.915 Q9EQW8 →
Q9JMI9 0.914 Q9JMI9 →
Q9EQH7 0.914 Q9EQH7 →